Want to see RNA full AI Analyst Report?
Atrium Therapeutics, Inc. (RNA) Income Statement
Atrium Therapeutics, Inc. Income Statement
Last quarter (Q2 2026), Atrium Therapeutics, Inc.'s total revenue was $3.00M, a decrease of 21.91% from the same quarter last year. In Q2, Atrium Therapeutics, Inc.'s net income was $-20.19M. See Atrium Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 18.62M | $ 10.90M | $ 9.56M | $ 9.22M | $ 9.33M | |
| $ 18.62M | $ 10.90M | $ 7.46M | $ 7.84M | $ -91.86M | |
| $ 95.43M | $ 389.83M | $ 243.06M | $ 186.75M | $ 26.20M | |
| Depreciation and Amortization | $ 323.00K | $ 2.78M | $ 2.10M | $ 1.39M | $ 639.00K |
| $ -76.50M | $ -376.16M | $ -233.50M | $ -177.53M | $ -117.41M | |
| $ -76.81M | $ -378.94M | $ -235.60M | $ -178.91M | $ -118.05M | |
| $ -12.00K | $ 56.63M | $ 23.38M | $ 4.92M | $ 42.00K | |
| $ -76.83M | $ -322.30M | $ -212.22M | $ -174.00M | $ -118.01M | |
| $ -76.68M | $ -322.30M | $ -212.22M | $ -174.00M | $ -118.01M | |
| Per Share Metrics | |||||
| Basic EPS | $ -4.48 | $ -2.89 | $ -2.91 | $ -3.34 | $ -2.85 |
| Diluted EPS | $ -4.48 | $ -2.89 | $ -2.91 | $ -3.34 | $ -2.85 |
| Weighted Average Shares Outstanding | 17.11M | 111.58M | 73.01M | 52.16M | 41.43M |
| Weighted Average Shares Outstanding (Diluted) | 17.11M | 111.58M | 73.01M | 52.16M | 41.43M |
Currency in USD
